- United States
- /
- Life Sciences
- /
- NasdaqGS:SEER
US$3.00: That's What Analysts Think Seer, Inc. (NASDAQ:SEER) Is Worth After Its Latest Results
Seer, Inc. (NASDAQ:SEER) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$4.2m beat estimates by a substantial 29% margin. Unfortunately, Seer also reported a statutory loss of US$0.34 per share, which at least was smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, the most recent consensus for Seer from three analysts is for revenues of US$17.4m in 2025. If met, it would imply a solid 14% increase on its revenue over the past 12 months. Losses are expected to be contained, narrowing 16% from last year to US$1.20. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$17.5m and losses of US$1.47 per share in 2025. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a cut to losses per share in particular.
View our latest analysis for Seer
Even with the lower forecast losses, the analysts lowered their valuations, with the average price target falling 57% to US$3.00. It looks likethe analysts have become less optimistic about the overall business.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Seer's rate of growth is expected to accelerate meaningfully, with the forecast 19% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 6.2% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 6.1% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Seer is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Seer's future valuation.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Seer analysts - going out to 2027, and you can see them free on our platform here.
And what about risks? Every company has them, and we've spotted 1 warning sign for Seer you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:SEER
Seer
A life sciences company, develops and commercializes products to decode the biology of the proteome.
Flawless balance sheet with limited growth.
Similar Companies
Market Insights
Community Narratives

